DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Monday 29 December 2014

C-aryl glucoside SGLT2 inhibitors and method US 6515117 B2


Figure US06515117-20030204-C00024
Dapagliflozin

http://www.google.co.in/patents/US6515117


HPLC retention time: 7.08 min, 94% pure, YMC S5 C-18 4.6×50 mm column, 2.5 mL/min, detection at 220 nM; 8 min gradient 0-100% B hold 5 min at 100% B. Solvent A: 10% MeOH/H2O+0.2% H3PO4. Solvent B: 90% MeOH/H2O+0.2% H3PO4.
1H NMP (500 MHz, CD3OD) δ7.33 (d, 1H, J=6 Hz), 7.31 (d, 1H, J=2.2 Hz), 7.31 (dd, 1H, J=6 Hz, J=2.2 Hz), 7.07 (d, 2H, J=8.8 Hz), 6.78 (d, 2H, J=8.8 Hz), 4.07-3.90 (m, 7H), 3.85 (d, 1H, J=10.6 Hz), 3.69 (dd, 1H, J=5.3, 10.6 Hz), 3.42-3.25 (m, 4H) Hz), 1.34 (t, 3H, J=7 Hz).
13C NMP (125 MHz, CD3OD) δ158.8, 140.0, 139.9, 134.4, 132.9, 131.9, 130.8, 130.1, 128.2, 115.5, 82.9, 82.2, 79.7, 76.4, 71.9, 64.5, 63.1, 39.2, 15.2.
Anal Calcd for C21H25ClOLC-MS [M+Na+]431; found 431.



Dapagliflozin
Dapagliflozin structure.svg
Systematic (IUPAC) name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
Clinical data
Trade namesForxiga, Farxiga
AHFS/Drugs.comUK Drug Information
Licence dataEMA:LinkUS FDA:link
Pregnancy cat.
Legal status
RoutesOral
Identifiers
CAS number461432-26-8 
ATC codeA10BX09
PubChemCID 9887712
ChemSpider8063384 Yes
UNII1ULL0QJ8UC Yes
ChEMBLCHEMBL429910 Yes
SynonymsBMS-512148
Chemical data
FormulaC21H25ClO6 
Mol. mass408.873 g/mol







Citing PatentFiling datePublication dateApplicantTitle
US6774112 *8 Apr 200210 Aug 2004Bristol-Myers Squibb CompanyAntidiabetic agents; cardiovascular disorders
US6936590 *4 Oct 200230 Aug 2005Bristol Myers Squibb CompanyTreating diabetic with a sodium dependent glucose transporters (SGLT2) inhibitors, especially type II diabetes; use of pyran compounds including dapaglifozin
US708412430 Jul 20041 Aug 2006Janssen Pharmaceutica, N.V.Antidiabetic agents; insulin resistance
US7094763 *30 Jul 200422 Aug 2006Janssen Pharaceutica, N.V.e.g., 2-(4-Ethylbenzyl)-4-( beta -D-glucopyranosyl)-1H-indole, used for the treatment or prophylaxis of diabetes and Syndrome X.
US709476430 Jul 200422 Aug 2006Janssen Pharmaceutica N.V.Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
US712922030 Jul 200431 Oct 2006Janssen Pharmaceutica N.VSubstituted indole-O-glucosides
US7169761 *4 Aug 200330 Jan 2007Astellas Pharma Inc.Azulene derivatives and salts thereof
US7199159 *23 May 20013 Apr 2007Centre National De La Recherche Scientifique (C.N.R.S.)Use of biguanide derivatives for making a medicine having a wound healing effect
US72387029 Feb 20063 Jul 2007Bristol-Myers Squibb CompanyDihydroquinazolinones as 5HT modulators
US7288528 *12 Dec 200330 Oct 2007Sanofi-Aventis Deutschland GmbhAromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
US737175921 Sep 200413 May 2008Bristol-Myers Squibb CompanyAnticholesterol agents; reducing blood serum lipids; anticancer agents; antiarthritic agents; antiinflammatory agents; antitumor agents; immunosuppressants; obesity; hypotensive agents
US737521323 Dec 200320 May 2008Bristol-Myers Squibb Companyinhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin
US741703227 Jul 200526 Aug 2008Boehringer Ingelheim International GmbhD-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture
US742005915 Nov 20042 Sep 2008Bristol-Myers Squibb CompanyHMG-CoA reductase inhibitors and method
US748233015 Jun 200627 Jan 2009Janssen Pharmaceutica N.V.3-(4-Ethylbenzyl)-5-( beta -D-glucopyranosyl)-1H-indole; antidiabetic agents; insulin resistance
US751102015 Jun 200631 Mar 2009Janssen Pharmaceutica N.V.2-[3-(4-Ethyl-benzyl)-3H-benzoimidazol-4-yloxy]- .squ. -D-glucoglucopyranoside; sodium glucose transporter inhibitor; antidiabetic agent; Syndrome X, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, and cataracts
US75110212 Jun 200631 Mar 2009Janssen Pharmaceutica N.V.2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-6-methyl-1H-indazol-4-yloxy} beta-D-glucopyranoside; sodium glucose transporter inhibitor; antidiabetic agent; Syndrome X, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, hypertension, ischemia, stroke, heart disease , and cataracts
US751102215 Jun 200631 Mar 2009Janssen Pharmaceutica N.V.Substituted indole-O-glucosides
US756669924 Mar 200428 Jul 2009Kissei Pharmaceutical Co., Ltd.Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
US757606330 Sep 200318 Aug 2009Kissei Pharmaceutical Co., Ltd.prevention or treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. 4-[(4-{3-[1-carbamoyl-1-(methyl)-ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole
US757944915 Mar 200525 Aug 2009Boehringer Ingelheim International GmbhMetabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene
US766279013 Apr 200616 Feb 2010Boehringer Ingelheim International GmbhGlucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US76668453 Dec 200723 Feb 2010Janssen Pharmaceutica N.V.Compounds having inhibitory activity against sodium-dependent glucose transporter
US768316029 Aug 200623 Mar 2010Boehringer Ingelheim International Gmbh1-chloro-4-( beta -D-glucopyranos-1-yl)-2-[4-((1R,2R)-2-hydroxy-cyclopent-1-yloxy)-benzyl]-benzene; metabolic disorders such as diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia; sodium-dependent glucose cotransporter SGLT2 inhibitors
US768746915 Dec 200530 Mar 2010Boehringer Ingelheim International GmbhGlucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US771393819 Apr 200611 May 2010Boehringer Ingelheim International GmbhCrystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US772330921 Apr 200625 May 2010Boehringer Ingelheim International GmbhCrystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US774541414 Feb 200729 Jun 2010Boehringer Ingelheim International GmbhGlucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US77721913 May 200610 Aug 2010Boehringer Ingelheim International GmbhProcesses for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US777237822 Feb 200610 Aug 2010Boehringer Ingelheim International Gmbhinhibiting sodium-dependent glucose cotransporter SGLT2; diabetes mellitus, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias, atherosclerosis, obesity, high blood pressure, chronic heart failure
US77768301 May 200717 Aug 2010Boehringer Ingelheim International Gmbhsodium-dependent glucose cotransporter (SGLT2) inhibitor; improved pharmacological or pharmacokinetic properties; antidiabetic agent, metabolic disorders, obesity, insulin resistance, atherosclerosis, chronic heart failure, liver fat
US778157727 Sep 200724 Aug 2010Lexicon Pharmaceuticals, Inc.2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents
US779543624 Aug 200614 Sep 2010Bristol-Myers Squibb Companycis-6-(2,4-Dichloro-phenyl)-1,2,3,4,4a,9a-hexahydro-3-aza-fluoren-9-one, used for treating metabolic disorders, nervous system disorders, headaches, gastrointestinal disorders and as analgesics
US781632811 Sep 200919 Oct 2010Janssen Pharmaceutica Nvsuch as 3-(4-Ethylbenzyl)-5-( beta -D-glucopyranosyl)-1H-indole, used for for treating diabetes, Syndrome X, or associated symptoms selected from obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke and cardiovascula disorders
US781633011 Sep 200919 Oct 2010Janssen Pharmaceutica NvSubstituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
US781633122 Sep 200919 Oct 2010Janssen Pharmaceutica NvSubstituted indazole-O-glucosides
US782063022 Sep 200926 Oct 2010Janssen Pharmaceutica NvSubstituted indole-O-glucosides
US783849922 Aug 200823 Nov 2010Theracos, Inc.(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-(2-methoxyethoxy)ethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; for treating diseases assoicated with sodium glucose co-transporter inhibition (SGLT) such as diabetes, hyperglycemia, insulin resistance, metabolic syndrome, atherosclerosis
US78469454 Mar 20087 Dec 2010Lexicon Pharmaceuticals, Inc.2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents
US784707414 Sep 20067 Dec 2010Boehringer Ingelheim International GmbhProcesses for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
US7851502 *21 Mar 200814 Dec 2010Bristol-Myers Squibb CompanyPharmaceutical formulations containing an SGLT2 inhibitor
US785160227 Jul 200614 Dec 2010Boehringer Ingelheim International GmbhGlucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US785161726 Jul 200714 Dec 2010Mitsubishi Tanabe Pharma CorporationIndole derivatives
US78884873 Aug 200915 Feb 2011Kissei Pharmaceutical Co., Ltd.Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
US7919598 *20 Jun 20075 Apr 2011Bristol-Myers Squibb CompanyCrystal structures of SGLT2 inhibitors and processes for preparing same
US793237919 Jun 200726 Apr 2011Bristol-Myers Squibb CompanyMethods of producing C-aryl glucoside SGLT2 inhibitors
US793567418 Jun 20093 May 2011Mitsubishi Tanabe Pharma CorporationIndole derivatives
US79435823 Dec 200717 May 2011Mitsubishi Tanabe Pharma CorporationCanagliflozin, a sodium-glucose transporter 2 inhibitor as antiobesity, antidiabetic agent; purity; handling characteristics; easy formulation; storage stability
US794365618 Apr 200817 May 2011Bristol-Myers Squibb CompanyCrystal forms of saxagliptin and processes for preparing same
US794378831 Jan 200517 May 2011Mitsubishi Tanabe Pharma CorporationGlucopyranoside compound
US802634717 Jul 200827 Sep 2011Lexicon Pharmaceuticals, Inc.Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
US808058024 Aug 200920 Dec 2011Pfizer Inc.Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US8088743 *21 Mar 20083 Jan 2012Bristol-Myers Squibb CompanySodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside
US81060211 Nov 201031 Jan 2012Theracos, Inc.Benzylbenzene derivatives and methods of use
US812943411 Dec 20086 Mar 2012Theracos, Inc.Benzylphenyl cyclohexane derivatives and methods of use
US819846420 Dec 200712 Jun 2012Astellas Pharma Inc.Method for producing C-glycoside derivative and intermediate for synthesis thereof
US820298413 Jan 201119 Jun 2012Mitsubishi Tanabe Pharma CorporationGlucopyranoside compound
US822178618 Nov 201017 Jul 2012Bristol-Myers Squibb CompanyPharmaceutical formulations containing an SGLT2 inhibitor
US82222191 Jul 201117 Jul 2012Mitsubishi Tanabe Pharma CorporationGlucopyranoside compound
US82368476 Apr 20117 Aug 2012Bristol-Myers Squibb CompanyCrystal forms of saxagliptin and processes for preparing same
US827826824 Oct 20072 Oct 2012Ortho-Mcneil Pharmaceutical, Inc.Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
US828345421 Aug 20099 Oct 2012Theracos, Inc.Processes for the preparation of SGLT2 inhibitors
US829387811 Aug 201123 Oct 2012Lexicon Pharmaceuticals, Inc.Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
US836197221 Jun 201229 Jan 2013Bristol Myers-Squibb CompanyPharmaceutical formulations containing an SGLT2 inhibitor
US847641318 Aug 20102 Jul 2013Lexicon Pharmaceuticals, Inc.Sulfanyl-tetrahydropyran-based compounds and methods of their use
US850169816 Mar 20116 Aug 2013Bristol-Myers Squibb CompanyCrystal structures of SGLT2 inhibitors and processes for preparing same
US85074507 Sep 200613 Aug 2013Boehringer Ingelheim International GmbhCrystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
US85132029 May 201120 Aug 2013Mitsubishi Tanabe Pharma CorporationCrystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
US855195715 Aug 20088 Oct 2013Boehringer Ingelheim International GmbhPharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US85577829 Jun 201015 Oct 2013Boehringer Ingelheim International GmbhGlucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US857532121 Dec 20115 Nov 2013Theracos, Inc.Benzylbenzene derivatives and methods of use
US8603989 *15 May 200910 Dec 2013Bristol-Myers Squibb CompanyMethod for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
US865252719 Mar 201318 Feb 2014Upsher-Smith Laboratories, IncExtended-release topiramate capsules
US866938021 Oct 201011 Mar 2014Pfizer Inc.Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US8685934 *26 May 20101 Apr 2014Bristol-Myers Squibb CompanyMethods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
US87162514 Jan 20136 May 2014Bristol-Myers Squibb CompanyPharmaceutical formulations containing an SGLT2 inhibitor
US87725128 Jul 20108 Jul 2014Janssen Pharmaceutica NvCrystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
US878540312 Jun 201222 Jul 2014Mitsubishi Tanabe Pharma CorporationGlucopyranoside compound
US8791077 *15 May 200929 Jul 2014Astrazeneca AbMethod for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
US880263730 Sep 201312 Aug 2014Theracos, Inc.Benzylbenzene derivatives and methods of use
US880271527 Dec 201312 Aug 2014Astrazeneca AbCrystal forms of saxagliptin and processes for preparing same
US880284228 Sep 201012 Aug 2014Boehringer Ingelheim International GmbhMethod for the preparation of a crystalline form
US20110003757 *29 Jan 20096 Jan 2011Astellas Pharma Inc.Pharmaceutical compositions for treating fatty liver disease
US20110065658 *15 May 200917 Mar 2011Bristol-Myers Squibb CompanyMethod for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US20110077213 *15 May 200931 Mar 2011Bristol-Myers Squibb CompanyMethod for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
US20110098240 *15 Aug 200828 Apr 2011Boehringer Ingelheim International GmbhPharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor
US20120041069 *18 Apr 201116 Feb 2012Nectid Inc.Sglt2 inhibitor dosage forms
US20120071403 *26 May 201022 Mar 2012Astrazeneca Uk LimitedMethods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof
US20120077739 *2 Dec 201129 Mar 2012Bristol-Myers SquibbMethods for treating obesity employing an sglt2 inhibitor and compositions thereof
US20130023486 *14 Jan 201124 Jan 2013Tianjin Institute Of Pharmaceutical ResearchPhenyl c-glucoside derivatives, preparation methods and uses thereof
CN102167715B7 Mar 201124 Apr 2013上海惠斯生物科技有限公司Eutectic preparation method of sodium-glucose cotransporter 2 bulk pharmaceutical chemicals
EP2308841A227 Sep 200713 Apr 2011Lexicon Pharmaceuticals, Inc.Phlorizin analogs as SGLT2 inhibitors
EP2455374A115 Oct 200923 May 2012Janssen Pharmaceutica N.V.Process for the Preparation of Compounds useful as inhibitors of SGLT
EP2457908A115 Oct 200930 May 2012Janssen Pharmaceutica N.V.Process for the Preparation of Compounds useful as inhibitors of SGLT
EP2457918A221 Jun 200730 May 2012Bristol-Myers Squibb CompanyCrystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes
EP2481726A218 Apr 20081 Aug 2012Bristol-Myers Squibb CompanyCrystal forms of saxagliptin and processes for preparing same
EP2514756A130 Jul 200424 Oct 2012Mitsubishi Tanabe Pharma CorporationNovel compounds having inhibitory activity against sodium-dependant glucose transporter
EP2668953A115 May 20094 Dec 2013Bristol-Myers Squibb CompanyPharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
WO2003099836A1 *15 May 20034 Dec 2003Squibb Bristol Myers CoC-aryl glucoside sglt2 inhibitors and method
WO2004080990A112 Mar 200423 Sep 2004Kazuhiro IkegaiC-glycoside derivatives and salts thereof
WO2005012318A2 *30 Jul 200410 Feb 2005Janssen Pharmaceutica NvSubstituted fused heterocyclic c-glycosides
WO2006019886A214 Jul 200523 Feb 2006Saleem AhmadPyrrolo(oxo)isoquinolines as 5ht ligands
WO2008006043A26 Jul 200710 Jan 2008Squibb Bristol Myers Co1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
WO2008042688A227 Sep 200710 Apr 2008Lexicon Pharmaceuticals IncPhlorizin analogs as inhibitors of sodium glucose co-transporter 2
WO2009035969A1 *9 Sep 200819 Mar 2009Janssen Pharmaceutica NvProcess for the preparation of compounds useful as inhibitors of sglt
WO2011051864A121 Oct 20105 May 2011Pfizer Inc.Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011060256A212 Nov 201019 May 2011Bristol-Myers Squibb CompanyBilayer tablet formulations
WO2011060290A212 Nov 201019 May 2011Bristol-Myer Squibb CompanyImmediate release tablet formulations
WO2011070592A29 Dec 201016 Jun 2011Panacea Biotec Ltd.Novel sugar derivatives
WO2011142478A111 May 201117 Nov 2011Mitsubishi Tanabe Pharma CorporationCanagliflozin containing tablets
WO2012031124A21 Sep 20118 Mar 2012Astrazeneca Uk LimitedDrug formulations using water soluble antioxidants
WO2012106303A131 Jan 20129 Aug 2012Astrazeneca Uk LimitedPharmaceutical formulations including an amine compound




No comments:

Post a Comment